Tyrosine kinase inhibitorPhase 3 trialInvestigational
Pazopanib
How it works
Blocks multiple proteins involved in cancer cell growth and survival, allowing the cancer cells to die.
Cancer types
Melanoma— All patients
Efficacy
In clinical trials, around 20-30% of patients achieved an objective response, with median progression-free survival of approximately 3-4 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.